# Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer

> **NCT01145430** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 45 (actual)

## Conditions studied

- Estrogen Receptor Negative
- HER2/Neu Negative
- Male Breast Carcinoma
- Progesterone Receptor Negative
- Recurrent Breast Carcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Stage IV Breast Cancer AJCC v6 and v7
- Triple-Negative Breast Carcinoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Pegylated Liposomal Doxorubicin Hydrochloride
- **OTHER:** Pharmacological Study
- **DRUG:** Veliparib

## Key facts

- **NCT ID:** NCT01145430
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06-01
- **Primary completion:** 2017-05-23
- **Final completion:** —
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2017-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01145430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01145430, "Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01145430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*